The city of Tampa, Florida, currently has 6 active clinical trials seeking participants for Crohn's Disease research studies.
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Recruiting
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab together with ustekinumab in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual targeted treatment. The study is conducted in two parts. In Part A, participants will receive the dual targeted treatment (vedolizumab together with either adalimumab or ustekinumab). In part B, participants will... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/20/2024
Locations: Alliance Clinical Research of Tampa, LLC, Tampa, Florida
Conditions: Crohn's Disease
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
Recruiting
The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/18/2024
Locations: GCP Clinical Research, Tampa, Florida
Conditions: Crohn's Disease
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
Recruiting
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effective risankizumab subcutaneous (SC) induction treatment is in treating moderately to severely active CD in adult participants. Risankizumab is an approved drug for adults with CD. This study comprises... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: GCP Clinical Research, LLC /ID# 260342, Tampa, Florida
Conditions: Crohn's Disease
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
Recruiting
This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn's disease (CD) who are refractory or intolerant to at least 1 of the current therapies for CD (ie, corticosteroids, immunosuppressants, or biologics). The overall duration of this study is up to 282 weeks, inclusive of the Screening Period, Treatment Period of up to 274 weeks (Induction, Exten... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/07/2024
Locations: Lab - Processing/ Storage, Tampa, Florida +7 locations
Conditions: Crohn's Disease
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Recruiting
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/06/2024
Locations: USF Tampa General Hospital, Tampa, Florida
Conditions: Crohn's Disease
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Recruiting
The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: USF Health, Tampa, Florida +1 locations
Conditions: Crohn's Disease